2024年10月17-19日，全球肝癌领域学术盛典——第十八届国际肝癌协会（ILCA）年会将在加拿大多伦多举行。全球肝癌专家将聚集在一起，探讨肝癌基础与临床的热点话题及最新进展！大会收录了全球肝癌领域的最新研究成果，本文特汇总其中治疗方面的重磅临床研究供广大同道学习交流。《肿瘤瞭望》和《国际肝病》特派记者将现场参会进行深入报道，更多精彩内容敬请期待！
ILCA 2024
最新临床研究进展，最热临床研究方向
5项大会口头报告
O-13
EMERALD-1研究结果：在不可切除的肝细胞癌受试者中，使用度伐利尤单抗联合/不联合贝伐珠单抗与经动脉化疗栓塞（TACE）的疗效
Analysis by treatment period and baseline liver function in EMERALD-1: a Phase 3, randomized, placebocontrolled study of durvalumab with/without bevacizumab with TACE in participants with embolization-eligible unresectable hepatocellular carcinoma
报告人：陈林（Stephen Chan）教授（中国香港）
O-14
基于靶向Glypican-3的嵌合抗体 （GPC3）的新型γ/δTCR治疗肝癌
A novel glypican-3-targeted chimeric antibody-based gamma/delta TCR for treating liver cancer
报告人：Dan Li, MD (USA)
O-15
度伐利尤单抗联合吉西他滨和顺铂治疗晚期胆道癌：一项全球范围内大规模真实世界研究
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer: a large real-life worldwide population
报告人：Lorenza Rimassa, PhD (Italy)
O-16
新辅助免疫治疗后的病理反应可预测肝细胞癌的无复发生存率
Pathological response following neoadjuvant immunotherapy predicts for relapse-free survival in hepatocellular carcinoma
报告人：Antonio D’Alessio, MD (UK)
经动脉化疗栓塞（TACE）联合或不联合仑伐替尼+帕博利珠单抗治疗中期肝细胞癌：III期临床研究
Transarterial Chemoembolization (TACE) With or Without Lenvatinib (len) + Pembrolizumab (pembro) for Intermediate-Stage Hepatocellular Carcinoma (HCC): Phase 3
报告人：Josep Maria Llovet, MD, PhD (Spain)
9项获奖优秀壁报
P-1
在不可切除肝细胞癌患者中，应答深度（DpR）和应答持续时间（DoR）与总生存期（OS）相关：IMbrave150探索性分析
Depth of response (DpR) and duration of response (DoR) are associated with overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC): Exploratory analyses of IMbrave150
报告人：Masatoshi Kudo, MD, PhD (Japan)
P-3
使用甲基化SEPT9与现有肿瘤标志物的联合指数作为早期肝细胞癌的筛查试验
Using a combined index of methylated SEPT9 with existing tumor markers as a screening test for early-stage hepatocellular carcinoma
报告人：Issei Saeki, MD, PhD (Japan)
P-9
安全网络化的医疗系统与肝细胞癌治疗延迟的关系
Association Between Safety Net Hospitals and Treatment Delays in Hepatocellular Carcinoma
报告人：Zach Whitham, MD (USA)
P-11
预测阿替利珠单抗联合贝伐珠单抗免疫治疗肝细胞癌应答的基因组生物学标志物：来自IMbrave150试验的启示
Genomic Biomarkers to Predict Response to Atezolizumab Plus Bevacizumab Immunotherapy in Hepatocellular Carcinoma: Insights from the IMbrave150 Trial
报告人：Sung Hwan Lee, MD (South Korea)
P-12
在TP53和CTNNB1遗传背景下未折叠蛋白反应在肝细胞癌中的作用
Unveiling the role of unfolded protein response in hepatocellular carcinoma behavior in TP53 and CTNNB1 genetic backgrounds
报告人：Stefany Infante, (Spain)
P-14
通过CRISPR编辑猪原代肝细胞建立肝细胞癌模型
Modeling Hepatocellular Carcinoma by CRISPR Editing of Porcine Primary Hepatocytes
报告人：Lobna Elkhadragy, MD (USA)
P-15
可预测顺铂/吉西他滨联合度伐利尤单抗治疗的胆管癌患者生存的广泛分子特征：全球大规模真实世界研究
Extensive molecular profiling in Predicting Survival in patients with cholangiocarcinoma treated with Cisplatin/gemcitabine plus durvalumab, a large real-life worldwide population
报告人：Lorenza Rimassa, MD (Italy)
P-16
联合抗PD-1治疗可缓解髓源性抑制细胞介导的免疫抑制，并减少不可逆电穿孔后肝细胞癌的复发
COMBINED ANTI-PD1 THERAPY RELIEVES MDSC-MEDIATED IMMUNOSUPPRESSION AND REDUCES HEPATOCELLULAR CARCINOMA REGROWTH AFTER IRREVERSIBLE ELECTROPORATION
报告人：匡铭教授
P-17
探索肝细胞癌新生抗原mRNA疫苗
EXPLORATION OF HEPATOCELLULAR CARCINOMA NEOANTIGEN MRNA VACCINE
报告人：高强教授
来源：《国际肝病》编辑部